Worldwide Liquid Biopsy (LBx) Market Forecasted to Grow at 29% p.a., Reaching $10.1B by 2029 – Market Report by DeciBio Consulting LLC
This third-edition of DeciBio’s liquid biopsy report takes an updated and comprehensive look at the LBx landscape. Informed by a combination of primary research, secondary research, and proprietary DeciBio databases and tools, this report provides a quantitative and qualitative assessment of the key LBx market segments.
Advancements in sensitivity and analytical capabilities are expanding the use-cases for liquid biopsy beyond genomic profiling to include minimal / molecular residual (MRD) testing, recurrence monitoring (surveillance), treatment response monitoring, and early cancer detection. While nascent today, these new applications represent significant global market expansion opportunities.
Report Methodology / Scope:
Report Details |
|
Research Methods |
|
2029 Market Size |
|
CAGR (2024-2029) |
29% |
Base Year |
2024 (current) |
Forecast Period |
2024-2029 |
Market / Forecast Currency |
USD |
Report Coverage |
Market size, segmentation, and forecast; key market players and trends; assays and technologies; market drivers and moderators; competitive analysis |
Segments Covered |
|
Learn more about DeciBio’s Oncology Liquid Biopsy (LBx) Market Report 2024 – 2029, here: https://www.decibio.com/product/global-oncology-liquid-biopsy-manufacturing-market-report
Selection of Liquid Biopsy Companies Mentioned:
- Adela
- AmoyDx
- Berry Oncology
- Biological Dynamics
-
Burning Rock Biotech -
Caris Life Sciences -
DELFI Diagnostics - Exact Sciences
-
Foresight Diagnostics - Foundation Medicine
- Freenome
-
Geneseeq Technology Inc. -
Genetron Holdings - GRAIL
- Guardant Health
- Illumina
- LabCorp / PGDx
-
Tempus - Thermo Fisher Scientific
- Natera
-
NeoGenomics (
Inivata ) - Personalis
- Predicine
- Roche
- SeekIn
-
Singlera Genomics -
Strata Oncology
Liquid Biopsy Market Analysis:
Market Drivers
The liquid biopsy market is poised for growth, driven by new evidence, updated guidelines, and expanded coverage that support broader application beyond primary use cases, such as therapy selection in lung cancer and MRD / monitoring in colorectal cancer. As new biomarkers emerge and companion diagnostics are approved, the demand for biomarker testing is on the rise. This increasing demand puts pressure on limited tissue samples and accelerates the adoption of LBx testing, particularly as patients become eligible for multiple LBx tests throughout their treatment journey. The availability of next-generation LBx assays, featuring improved performance and the ability to detect emerging biomarkers, expands the use cases for LBx testing and advances translational research in pharma. While the
Market Moderators
Test cost and the pace and level of payor coverage remains a challenge for liquid biopsy testing, especially outside of lung cancer and in ex-
About DeciBio:
Headquartered in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240725768770/en/
rebecca.burnham@decibio.com
310.451.4510
Source: